“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 28/03/2023
EUR9.11
▲ −0.84 (−8.44%)
Market capitalisation
EUR36m
SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
Consumer
Consumer
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (18.2) | (12.1) | (56.2) |
| Relative | (16.9) | (18.6) | (58.6) |
| 52 week high/low | €19.6/€9.0 |
SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.
